K A Jellinger

Summary

Affiliation: University of Vienna
Country: Austria

Publications

  1. ncbi The morphological basis of mental dysfunction in Parkinson's disease
    K A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, A 1070 Vienna, Austria
    J Neurol Sci 248:167-72. 2006
  2. ncbi Alzheimer 100--highlights in the history of Alzheimer research
    K A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Neural Transm 113:1603-23. 2006
  3. ncbi Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Cell Mol Med 12:1094-117. 2008
  4. ncbi A critical reappraisal of current staging of Lewy-related pathology in human brain
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070, Vienna, Austria
    Acta Neuropathol 116:1-16. 2008
  5. ncbi Mild cognitive impairment in Parkinson disease: heterogenous mechanisms
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070, Vienna, Austria
    J Neural Transm 120:157-67. 2013
  6. ncbi Neurobiology of cognitive impairment in Parkinson's disease
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, A 1070 Vienna, Austria
    Expert Rev Neurother 12:1451-66. 2012
  7. ncbi Cerebral correlates of psychotic syndromes in neurodegenerative diseases
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Cell Mol Med 16:995-1012. 2012
  8. ncbi Neuropathology and general autopsy findings in nondemented aged subjects
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Clin Neuropathol 31:87-98. 2012
  9. ncbi CSF biomarkers in different phenotypes of Parkinson disease
    Kurt A Jellinger
    J Neural Transm 119:455-6. 2012
  10. ncbi Heterogenous mechanisms of mild cognitive impairment in Parkinson's disease
    Kurt Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Neural Transm 119:381-2. 2012

Detail Information

Publications108 found, 100 shown here

  1. ncbi The morphological basis of mental dysfunction in Parkinson's disease
    K A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, A 1070 Vienna, Austria
    J Neurol Sci 248:167-72. 2006
    ....
  2. ncbi Alzheimer 100--highlights in the history of Alzheimer research
    K A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Neural Transm 113:1603-23. 2006
    ....
  3. ncbi Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Cell Mol Med 12:1094-117. 2008
    ..It is suggested that ALZAS represents an indicator in a dynamic equilibrium between both peripheral and brain degenerative changes in AD and may become a useful "non-invasive" diagnostic marker via a simple blood test...
  4. ncbi A critical reappraisal of current staging of Lewy-related pathology in human brain
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070, Vienna, Austria
    Acta Neuropathol 116:1-16. 2008
    ....
  5. ncbi Mild cognitive impairment in Parkinson disease: heterogenous mechanisms
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070, Vienna, Austria
    J Neural Transm 120:157-67. 2013
    ..Prospective studies using specific biomarkers, including amyloid imaging, and cerebro-spinal fluid biomarkers are warranted for an exact diagnosis and prognostic assessment of early cognitive deficits in PD patients...
  6. ncbi Neurobiology of cognitive impairment in Parkinson's disease
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, A 1070 Vienna, Austria
    Expert Rev Neurother 12:1451-66. 2012
    ..PDD and dementia with Lewy bodies are considered similar parts of a disease spectrum. Treatment with cholinesterase inhibitors revealed mild-to-moderate results...
  7. ncbi Cerebral correlates of psychotic syndromes in neurodegenerative diseases
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Cell Mol Med 16:995-1012. 2012
    ..A better understanding of the pathophysiology and distinctive pathological features underlying the development of PS in neurodegenerative diseases may provide important insights into psychotic processes in general...
  8. ncbi Neuropathology and general autopsy findings in nondemented aged subjects
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Clin Neuropathol 31:87-98. 2012
    ..6 y). The importance of mixed pathologies in nondemented elderly, being less frequent than in other studies, remains to be elucidated...
  9. ncbi CSF biomarkers in different phenotypes of Parkinson disease
    Kurt A Jellinger
    J Neural Transm 119:455-6. 2012
    ..01). These data in a small cohort confirm previous studies, corroborating the opinion that CSF levels of tau protein and the index total-tau/Aβ-42 may be potential markers of the severity of neurodegeneration in PD...
  10. ncbi Heterogenous mechanisms of mild cognitive impairment in Parkinson's disease
    Kurt Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Neural Transm 119:381-2. 2012
    ..Prospective studies using specific biomarkers, including amyloid imaging and CSF biomarkers are important for the diagnosis and prognostic assessment of early cognitive deficits in PD patients...
  11. ncbi Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype
    K A Jellinger
    L Boltzmann Institute of Clinical Neurobiology, Baumgartner Hoehe 1, B Bldg, A 1140 Vienna, Austria
    BMC Neurol 1:3. 2001
    ..The impact of traumatic brain injury (TBI) on the pathogenesis of Alzheimer disease (AD) is still controversial. The aim of our retrospective autopsy study was to assess the impact of TBE and ApoE allele frequency on the development of AD...
  12. ncbi 5th International Congress on the Improvement of the Quality of Life on Dementia, Parkinson's disease, Epilepsy, Multiple Sclerosis and Muscular Disorders
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, A-1070 Vienna, Austria
    Expert Rev Neurother 7:241-3. 2007
  13. ncbi In memoriam: Franz Seitelberger (1916-2007)
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Medical University of Vienna, Kenyongasse 18, Vienna, 1070, Austria
    Acta Neuropathol 115:157-8. 2008
  14. ncbi Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Acta Neuropathol 115:427-36. 2008
    ....
  15. ncbi Cerebral amyloid angiopathy in Lewy body disease
    K A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Neural Transm 115:473-82. 2008
    ..This and other recent studies imply an association of CAA with cognitive decline in both PD/PDD and DLB, particularly in cases with concomitant AD-type pathology...
  16. ncbi Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Neurodegener Dis 5:118-21. 2008
    ..Proteinopathies are a heterogenous group of neurodegenerative disorders, characterized by intra- and extracellular accumulation of abnormal filament proteins...
  17. ncbi Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Neurodegener Dis 5:339-46. 2008
    ....
  18. ncbi The enigma of vascular cognitive disorder and vascular dementia
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070, Vienna, Austria
    Acta Neuropathol 113:349-88. 2007
    ....
  19. ncbi Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease
    K A Jellinger
    Institute of Clinical Neurobiology, 18, Kenyongasse, 1070, Vienna, Austria
    Acta Neuropathol 113:107-17. 2007
    ..Comparing 51 autopsy cases of NFTPD with 244 classical AD subjects, the nosology of NFTPD and its differences from AD are discussed...
  20. ncbi Grading of neuropathology in multiple system atrophy: proposal for a novel scale
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Mov Disord 20:S29-36. 2005
    ....
  21. ncbi A short history of neurosciences in Austria
    K A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Neural Transm 113:271-82. 2006
    ....
  22. ncbi Prevalence and impact of cerebrovascular pathology in Alzheimer's disease and parkinsonism
    K A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Acta Neurol Scand 114:38-46. 2006
    ..To study the prevalence and impact of cerebrovascular lesions (CVL) in Alzheimer's disease (AD) and their effects on cognitive impairment...
  23. ncbi Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070 Vienna, Austria
    Acta Neuropathol 112:253-60. 2006
    ..Differences in AS and Abeta pathologies and much less of tau lesions in the striatum support a morphologic distinction between PDD and DLB, which may be of pathophysiologic importance, but the causes of these differences are unclear...
  24. ncbi Clinicopathological analysis of dementia disorders in the elderly--an update
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, A 1070 Vienna, Austria
    J Alzheimers Dis 9:61-70. 2006
    ..The present study and the results of other recent series indicate increasing agreement between clinical and autopsy diagnoses in demented aged individuals with variable accuracy rates for different forms of dementia disorders...
  25. ncbi Challenges in neuronal apoptosis
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, A 1070 Vienna, Austria
    Curr Alzheimer Res 3:377-91. 2006
    ....
  26. ncbi Morphologic diagnosis of "vascular dementia" - a critical update
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, A 1070 Vienna, Austria
    J Neurol Sci 270:1-12. 2008
    ..Harmonization of neuropathologic procedures and evaluation criteria in future prospective clinico-pathologic studies are needed to validate diagnostic criteria for VaD and to clarify the impact of vascular lesions on cognition...
  27. ncbi The pathology of "vascular dementia": a critical update
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Alzheimers Dis 14:107-23. 2008
    ..Further prospective clinico-pathologic studies are needed to validate diagnostic criteria for VaD and to clarify the impact of vascular lesions on cognitive impairment...
  28. ncbi Synuclein deposition and non-motor symptoms in Parkinson disease
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, A 1070 Vienna, Austria
    J Neurol Sci 310:107-11. 2011
    ....
  29. ncbi Prevalence and pathology of vascular dementia in the oldest-old
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Alzheimers Dis 21:1283-93. 2010
    ....
  30. ncbi Prevalence and pathology of dementia with Lewy bodies in the oldest old: a comparison with other dementing disorders
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Dement Geriatr Cogn Disord 31:309-16. 2011
    ..A retrospective hospital-based study compared the relative prevalence of DLB among very old individuals...
  31. ncbi Interaction between α-synuclein and tau in Parkinson's disease comment on Wills et al.: elevated tauopathy and α-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218
    Kurt A Jellinger
    Institute of Clinical Neurobiology, A 1070, Vienna, Austria
    Exp Neurol 227:13-8. 2011
    ....
  32. ncbi Four-repeat tauopathy clinically presenting as posterior cortical atrophy: atypical corticobasal degeneration?
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Acta Neuropathol 121:267-77. 2011
    ..This is the first published case with the fully developed clinical and neuroimaging picture of posterior cortical atrophy, morphologically presenting as a distinct phenotype of 4R-tauopathy that closely resembles (atypical) CBD...
  33. ncbi Con: Can neuropathology really confirm the exact diagnosis?
    Kurt A Jellinger
    Institute of Clinical Neurobiology, 18 Kenyongasse, A 1070 Vienna, Austria
    Alzheimers Res Ther 2:11. 2010
    ..The value and pitfalls of pathological diagnostic criteria are critically discussed...
  34. ncbi Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070 Vienna, Austria
    Acta Neuropathol 119:657-67. 2010
    ..The relationship between oligodendrocytes involved by Papp-Lantos inclusions and those in degenerating neurons in the course of MSA needs further elucidation...
  35. ncbi Prevalence of dementia disorders in the oldest-old: an autopsy study
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070, Vienna, Austria
    Acta Neuropathol 119:421-33. 2010
    ....
  36. ncbi Prevalence and impact of cerebrovascular lesions in Alzheimer and lewy body diseases
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, AT 1070 Vienna, Austria
    Neurodegener Dis 7:112-5. 2010
    ..Data on the prevalence of cerebrovascular lesions (CVLs) and their impact on cognitive decline in Alzheimer disease (AD) and Lewy body disease are conflicting...
  37. ncbi Basic mechanisms of neurodegeneration: a critical update
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse, Vienna, Austria
    J Cell Mol Med 14:457-87. 2010
    ..Animal models and other studies have provided insight into the basic neurodegeneration and cell death programs, offering new ways for future prevention/treatment strategies...
  38. ncbi Recent advances in our understanding of neurodegeneration
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Neural Transm 116:1111-62. 2009
    ....
  39. ncbi [Functional pathophysiology of consciousness]
    Kurt A Jellinger
    Institut für Klinische Neurobiologie, Wien
    Neuropsychiatr 23:115-33. 2009
    ....
  40. ncbi Absence of alpha-synuclein pathology in postencephalitic parkinsonism
    Kurt A Jellinger
    Institute of Clinical Neurobiology, 1070 Vienna, Austria
    Acta Neuropathol 118:371-9. 2009
    ..The causes and molecular background of total absence of alpha-synuclein pathology in PEP, in contrast to most other tauopathies, remain as unknown as the pathogenesis of PEP...
  41. ncbi Lewy body/alpha-synucleinopathy in schizophrenia and depression: a preliminary neuropathological study
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070, Vienna, Austria
    Acta Neuropathol 117:423-7. 2009
    ..Among chronic affective disorders, according to our small cohort, the incidence of Lewy-pathology in LLD appears to be comparable to a healthy elderly population, whereas its occurence in BD is to be elucidated...
  42. ncbi Significance of brain lesions in Parkinson disease dementia and Lewy body dementia
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Front Neurol Neurosci 24:114-25. 2009
    ..In conclusion, the pathology underlying cognitive impairment in PDD and DLB is heterogeneous, but there are some differences in the topography and severity of lesions between both phenotypes that need further evaluation...
  43. ncbi Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070, Vienna, Austria
    Acta Neuropathol 117:101-10. 2009
    ..The detection of disease-specific pathologies will be indispensable to determinate the efficacy of new therapy options...
  44. ncbi Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Mov Disord 27:8-30. 2012
    ....
  45. ncbi Predictors of survival in dementia with lewy bodies and Parkinson dementia
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Neurodegener Dis 4:428-30. 2007
    ..Associated Alzheimer pathology also shortened survival. When adjusted for age, gender, and Alzheimer pathology, fluctuating dementia at symptom onset was identified as best predictor of poor outcome...
  46. ncbi [Principles and application of acupuncture in neurology]
    K A Jellinger
    Ludwig Boltzmann Institut für Klinische Neurobiologie, Wien
    Wien Med Wochenschr 150:278-85. 2000
    ..There is sufficient evidence of acupuncture to expand its use into conventional medicine and to encourage further studies of its pathophysiology and clinical value...
  47. ncbi Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070 Vienna, Austria
    Acta Neuropathol 106:191-201. 2003
    ..The relationship between AD and PD with particular reference to alpha-synuclein-positive lesions needs further elucidation [corrected]...
  48. ncbi Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients
    N Rosler
    Ludwig Boltzmann Institute of Clinical Neurobiology, Vienna, Austria
    J Neural Transm 108:231-46. 2001
    ....
  49. ncbi Senile dementia with tangles (tangle predominant form of senile dementia)
    K A Jellinger
    Ludwig Boltzmann Institute of Clinical Neurobiology, Vienna, Austria
    Brain Pathol 8:367-76. 1998
    ..Senile dementia with tangles is suggested to be a variant of Alzheimer disease occurring in the oldest-old, but its nosological position within aging disorders of the brain is still controversy...
  50. ncbi Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease
    K A Jellinger
    L Boltzmann Institute of Clinical Neurobiology, Vienna, Austria, Institute of Neuropathology, University of Münster School of Medicine, Munster, Germany
    Eur J Neurol 8:707-10. 2001
    ..The results of this first retrospective autopsy study of TBI, ApoE allele frequency, and AD confirms clinical studies suggesting severe TBI to be a risk factor for the development of AD particularly in subjects lacking ApoEepsilon4...
  51. ncbi Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease
    K A Jellinger
    L Boltzmann Institute of Clinical Neurobiology, Vienna, Austria
    J Neural Transm 109:329-39. 2002
    ..To assess the impact of coexisting Alzheimer (AD) pathology on the natural history of Parkinson's disease (PD)...
  52. ncbi Cell death mechanisms in neurodegeneration
    K A Jellinger
    Ludwig Boltzmann Institute of Clinical Neurobiology, PKH B Building Baumgartner Hoehe 1, A 1140 Vienna, Austria
    J Cell Mol Med 5:1-17. 2001
    ....
  53. ncbi Alzheimer disease and cerebrovascular pathology: an update
    K A Jellinger
    Ludwig Boltzmann Institute of Clinical Neurobiology, Otto Wagner Hospital, Vienna, Austria
    J Neural Transm 109:813-36. 2002
    ..Further studies will help to elucidate the risk factors and impact of cerebrovascular lesions on the development and progression of dementia in AD...
  54. ncbi The pathology of ischemic-vascular dementia: an update
    Kurt A Jellinger
    Ludwig Boltzmann Institute of Clinical Neurobiology, Otto Wagner Hospital, B Bildg, 1, Baumgartner Hoehe, A 1140 Vienna, Austria
    J Neurol Sci 203:153-7. 2002
    ....
  55. ncbi Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study
    Kurt A Jellinger
    Institute of Clinical Neurobiology, 18 Kenyongasse, 1070 Vienna, Austria
    Acta Neuropathol 105:14-7. 2003
    ....
  56. ncbi Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18 7, 1070 Vienna, Austria
    Acta Neuropathol 105:415-9. 2003
    ..Cognitive impairment in PD appears to be largely independent from coexistent vascular pathology except in cases with severe cerebrovascular lesions...
  57. ncbi Neuropathological spectrum of synucleinopathies
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Mov Disord 18:S2-12. 2003
    ....
  58. ncbi Rett Syndrome -- an update
    K A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Neural Transm 110:681-701. 2003
    ..Current treatment includes symptomatic, anticonvulsive and physiotherapy...
  59. ncbi Head injury and dementia
    Kurt A Jellinger
    Institute of Clinical Neurobiology, A 1070 Vienna, Austria
    Curr Opin Neurol 17:719-23. 2004
    ..The link between head injury and dementia/Alzheimer's disease is controversial. This review discusses some recent epidemiological, human autopsy and experimental studies on the relationship between traumatic head injury and dementia...
  60. ncbi Neuropathology and general autopsy findings in AIDS during the last 15 years
    K A Jellinger
    Ludwig Boltzmann Institute of Clinical Neurobiology, Vienna, Austria
    Acta Neuropathol 100:213-20. 2000
    ....
  61. ncbi No increased incidence of Alzheimer's disease in elderly schizophrenics
    K A Jellinger
    Ludwig Boltzmann Institute of Clinical Neurobiology, PKH, Vienna, Austria
    Acta Neuropathol 97:165-9. 1999
    ..The reasons for this negative association and the basis of cognitive deficits in elderly schizophrenics--those with dementia usually showing significantly lower brain weight--await further elucidation...
  62. ncbi The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease
    K A Jellinger
    Ludwig Boltzmann Institute of Clinical Neurobiology, Vienna, Austria
    Drugs Aging 14:115-40. 1999
    ..Although experimental and preclinical data suggest the therapeutic potential of these drugs, their clinical applicability will be a major challenge for future research...
  63. ncbi Dementia with grains (argyrophilic grain disease)
    K A Jellinger
    Ludwig Boltzmann Institute of Clinical Neurobiology, Vienna, Austria
    Brain Pathol 8:377-86. 1998
    ..The prevalence and pathogenesis of this condition, its clinicopathologic correlations and nosological position among tau-pathology related disorders await further elucidation...
  64. ncbi Understanding the pathology of vascular cognitive impairment
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, A 1070 Vienna, Austria
    J Neurol Sci 229:57-63. 2005
    ..AD pathology is significantly less severe in the presence of cerebrovascular lesions. Further studies are needed to validate diagnostic criteria for VCI and to clarify the impact of vascular lesions on cognitive impairment...
  65. ncbi Pathology and pathophysiology of vascular cognitive impairment. A critical update
    K A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Panminerva Med 46:217-26. 2004
    ..Further studies are needed to validate diagnostic criteria for VaD/VCI and to clarify the impact of vascular lesions on cognitive impairment as a basis for more precise clinical diagnosis, early prevention and management...
  66. ncbi Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, A 1070 Vienna, Austria
    J Neurol Sci 229:37-41. 2005
    ..Considering the variability of vascular pathology in both AD and aged brains, the mechanisms behind their interactions are largely unknown, and further studies are needed to clarify their impact on cognitive impairment...
  67. ncbi What is new in degenerative dementia disorders?
    K A Jellinger
    L Boltzmann Institut für Klinische Neurobiologie, KH Wien Lainz, Austria
    Wien Klin Wochenschr 111:682-704. 1999
    ..In the future, these options will hopefully be replaced by more effective management strategies in order to improve the quality of life of both, patients and caregivers...
  68. ncbi Cell death mechanisms in Parkinson's disease
    K A Jellinger
    Ludwig Boltzmann Institute of Clinical Neurobiology, Psychiatric Hospital, Vienna, Austria
    J Neural Transm 107:1-29. 2000
    ..passive cell death (apoptosis vs. necrosis), mainly based on conflicting results on the rare presence or absence of DNA fragmentation in substantia nigra neurons using the in situ DNA-labeling (TUNEL) method...
  69. ncbi Mechanisms of cell death in neurodegenerative disorders
    K A Jellinger
    Ludwig Boltzmann Institute of Clinical Neurobiology, Psychiatric Hospital, Vienna, Austria
    J Neural Transm Suppl 59:95-114. 2000
    ..However, DNA fragmention in neurons is too frequent to account for the continuous loss in these slowly progressive diseases...
  70. ncbi Interaction between α-synuclein and other proteins in neurodegenerative disorders
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, A 1070 Vienna, Austria
    ScientificWorldJournal 11:1893-907. 2011
    ....
  71. ncbi Unexpectedly low prevalence of intracerebral hemorrhages in sporadic cerebral amyloid angiopathy: an autopsy study
    Johannes Attems
    Institute of Pathology, Otto Wagner Hospital, Baumgartner Hoehe 1, 1145, Vienna, Austria
    J Neurol 255:70-6. 2008
    ..Hence, the role of APOE in the pathogenesis of ICH with and without CAA needs further elucidation...
  72. ncbi Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology--a pilot study
    Johannes Attems
    Institute of Pathology, Otto Wagner Hospital, Baumgartner Hoehe 1, 1140 Vienna, Austria
    Acta Neuropathol (Berl) 107:83-90. 2004
    ..Studies to answer the question whether CapCAA represents an epiphenomenon or an indicator of a pathogenic association between tau cytopathology and Abeta deposition in capillaries are in progress...
  73. ncbi Olfactory tau pathology in Alzheimer disease and mild cognitive impairment
    J Attems
    Department of Pathology, Otto Wagner Hospital, Vienna, Austria
    Clin Neuropathol 25:265-71. 2006
    ..Clinical dementia correlated with both Braak and olfactory tau scores, indicating that both are associated with a high risk of cognitive decline...
  74. ncbi Lewy bodies in patients presenting clinically with Alzheimer disease
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Alzheimers Dis 4:327-8. 2002
  75. ncbi Olfactory involvement in aging and Alzheimer's disease: an autopsy study
    Johannes Attems
    Institute of Pathology, O. Wagner Hospital, Vienna, Austria
    J Alzheimers Dis 7:149-57; discussion 173-80. 2005
    ..Since the involvement of both systems is associated with a high risk of cognitive decline, future studies should validate the sensitivity of olfactory mucosa biopsies in the diagnosis of Alzheimer's disease...
  76. ncbi Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy
    Johannes Attems
    Pathological Institute, Otto Wagner Hospital, , 1140, Vienna, Austria
    Acta Neuropathol 110:222-31. 2005
    ..01), and was independent of APOE genotype. Our results suggest that progressing AD pathology not only increases the severity of CAA, but also shifts its topographical distribution towards the occipital cortex...
  77. ncbi Morphological substrates of mental dysfunction in Lewy body disease: an update
    K A Jellinger
    Ludwig Boltzmann Institute of Clinical Neurobiology, Vienna, Austria
    J Neural Transm Suppl 59:185-212. 2000
    ..The specific contributions of cortical and subcortical pathologies to mental dysfunction in PD and related disorders, their relationship to AD, and their genetic and aetiological backgrounds await further elucidation...
  78. ncbi Prevalence of vascular lesions in dementia with Lewy bodies. A postmortem study
    K A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Neural Transm 110:771-8. 2003
    ..On the other hand, like in PD and AD, cognitive impairment in DLB appears to be independent from coexisting vascular pathology and is mainly related to neuritic Alzheimer pathology...
  79. ncbi Lewy body-related alpha-synucleinopathy in the aged human brain
    K A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Neural Transm 111:1219-35. 2004
    ..However, the basic mechanisms of LB-related AS-pathology and their pathogenic and clinical relevance in aged brain and neurodegenerative disorders await further elucidation...
  80. ncbi Highlights in the history of neurosciences in Austria--review
    K A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Clin Neuropathol 25:243-52. 2006
  81. ncbi Neuropathological evaluation of mixed dementia
    K A Jellinger
    Institute of Clinical Neurobiology, 18, Kenyongasse, A 1070 Vienna, Austria
    J Neurol Sci 257:80-7. 2007
    ..Therefore, more distinct and critically evaluated clinico-pathological criteria are warranted...
  82. ncbi Sporadic cerebral amyloid angiopathy is not a frequent cause of spontaneous brain hemorrhage
    K A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse, Vienna, Austria
    Eur J Neurol 14:923-8. 2007
    ....
  83. ncbi Amyloid beta peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology
    Johannes Attems
    Institute of Pathology, Otto Wagner Hospital, Baumgartner Hoehe 1, 1140, Vienna, Austria
    Acta Neuropathol 107:283-91. 2004
    ..These data support the concept of a neuronal origin of Abeta via drainage from interstitial fluid from the central nervous system along basement membranes to capillaries...
  84. ncbi Formation and development of Lewy pathology: a critical update
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070, Vienna, Austria
    J Neurol 256:270-9. 2009
    ..If robust correlations between clinical course and Lewy/alpha Syn pathology are to be confirmed by future studies, the currently used morphologic staging/classification systems should be revised accordingly...
  85. ncbi Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology
    Johannes Attems
    Institute of Pathology, Otto Wagner Hospital, Baumgartner Hohe 1, A 1145, Vienna, Austria
    J Neurol Sci 257:49-55. 2007
    ..These results indicate a strong association of AD with CAA, but do not unequivocally support reports suggesting CAA to be an independent risk factor for cognitive decline, except for a subgroup of demented patients lacking any ADP...
  86. ncbi The impact of cerebrovascular lesions in Alzheimer disease--a comparative autopsy study
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070 Vienna, Austria
    J Neurol 250:1050-5. 2003
    ....
  87. ncbi A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders
    Kurt A Jellinger
    Institute of Clinical Neurobiology Kenyongasse 18, Vienna, Austria
    Biochim Biophys Acta 1792:730-40. 2009
    ....
  88. ncbi Is there pure vascular dementia in old age?
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    J Neurol Sci 299:150-4. 2010
    ....
  89. ncbi Ex vivo lumbar and post mortem ventricular cerebrospinal fluid substance P-immunoreactivity in Alzheimer's disease patients
    N Rosler
    Ludwig Boltzmann Institute of Clinical Neurobiology, PKH B Building, Baumgartner Hohe 1, A 1140 Vienna, Austria
    Neurosci Lett 299:117-20. 2001
    ..It is concluded that CSF SPIR may not serve as a diagnostic marker for AD, but possibly could reflect immunological or neuroprotective processes modulated by substance P in late onset AD patients...
  90. ncbi Alzheimer pathology in the olfactory bulb
    K A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Neuropathol Appl Neurobiol 31:203. 2005
  91. ncbi Tau and alpha-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs
    Johannes Attems
    Institute of Pathology, Otto Wagner Hospital, Vienna, Austria
    Acta Neuropathol 113:53-62. 2007
    ..However, often associated with nigral tau lesions and higher Braak stages, EPS in elderly patients may be a surrogate marker for severe neuritic AD pathology...
  92. ncbi Intra vitam lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin-6 in Alzheimer's disease patients
    N Rosler
    Ludwig Boltzmann Institute of Clinical Neurobiology, Vienna, Austria
    Acta Neurol Scand 103:126-30. 2001
    ..In view of contradictory findings in previous studies, to examine the diagnostic value of interleukin-6 measurements in cerebrospinal fluid (CSF) of Alzheimer's disease patients...
  93. ncbi Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics
    M Rainer
    Memory-Clinic and Department of Psychiatry, Donauspital, Sozialmedizinisches Zentrum Ost, Vienna, Austria
    J Neural Transm 108:1327-33. 2001
    ..Its magnitude was comparable to the cognitive response observed in published clinical trials when cholinesterase therapy commenced, and also with the data obtained during a 6-week placebo washout phase...
  94. ncbi Cause of death in demented and non-demented elderly inpatients; an autopsy study of 308 cases
    Johannes Attems
    Otto Wagner Hospital, Department of Pathology, Baumgartner Hohe 1, A 1145 Vienna, Austria
    J Alzheimers Dis 8:57-62. 2005
    ..Our data emphasize the high incidence of bronchopneumonia as a COD in patients suffering from AD...
  95. ncbi Hippocampal sclerosis in Alzheimer disease and other dementias
    Johannes Attems
    Department of Pathology, Otto Wagner Hospital, Vienna, Austria
    Neurology 66:775. 2006
  96. ncbi Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies
    Kurt A Jellinger
    Neurology 62:160; author reply 160. 2004
  97. ncbi Pathological substrate of dementia in Parkinson's disease--its relation to DLB and DLBD
    Kurt A Jellinger
    Parkinsonism Relat Disord 12:119-20. 2006
  98. ncbi P25alpha immunoreactivity in multiple system atrophy and Parkinson disease
    Kurt A Jellinger
    Acta Neuropathol 112:112. 2006
  99. ncbi The role of alpha-synuclein in the pathogenesis of multiple system atrophy
    Gregor K Wenning
    Department of Neurology, University of Innsbruck, School of Medicine, Anichstrasse 35, 6020, Innsbruck, Austria
    Acta Neuropathol (Berl) 109:129-40. 2005
    ..Transgenic MSA mouse models are now available to determine these aspects of cellular disturbance experimentally...
  100. ncbi Prevalence of stroke in Parkinson's disease
    Kurt A Jellinger
    Mov Disord 18:723-4. 2003
  101. ncbi Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple system atrophy)
    Laura Mantoan
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria
    Acta Neuropathol (Berl) 109:191-7. 2005
    ....